Cardlytics (CDLX) Current Deferred Revenue (2017 - 2026)

Cardlytics' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• Quarterly Current Deferred Revenue rose 4.98% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 4.98% YoY) and the FY2025 annual result came in at $2.5 million, up 17.97% from the prior year.
• Current Deferred Revenue was $2.7 million for Q1 2026 at Cardlytics, up from $2.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $4.7 million in Q2 2022 and bottomed at $412000.0 in Q3 2025.
• A 5-year average of $2.4 million and a median of $2.4 million in 2023 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 466.41% — and 2025, when it plunged 80.03%.
• Cardlytics' Current Deferred Revenue stood at $1.8 million in 2022, then surged by 37.35% to $2.4 million in 2023, then retreated by 10.44% to $2.2 million in 2024, then grew by 17.97% to $2.5 million in 2025, then advanced by 7.75% to $2.7 million in 2026.
• Business Quant data shows CDLX's Current Deferred Revenue at $2.7 million in Q1 2026, $2.5 million in Q4 2025, and $412000.0 in Q3 2025.